Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
BeiGene Ltd ( (HK:6160) ) has shared an update.
BeiGene Ltd announced the grant of share options and restricted share units under its 2016 Share Option and Incentive Plan. The company granted options to subscribe for 2,271 American Depositary Shares (ADSs) to one grantee and issued 35,469 restricted share units (RSUs) to 108 grantees. This move is part of BeiGene’s strategy to incentivize its employees and align them with the company’s long-term goals, potentially enhancing employee retention and motivation. This grant represents a minor fraction of the company’s total issued shares, reflecting a targeted approach to employee compensation.
More about BeiGene Ltd
BeiGene Ltd is a biotechnology company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drug candidates for the treatment of cancer.
YTD Price Performance: -0.09%
Average Trading Volume: 2,118,810
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$158.1B
For a thorough assessment of 6160 stock, go to TipRanks’ Stock Analysis page.